Cytogen, Inc. (KOSDAQ:217330)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Liquid Biopsy Application Business	866.06M	615.15M	347.85M
Liquid Biopsy Application Business Growth	40.79%	76.85%	-
Toxicity and Molecular Diagnostic Tests	2.32B	145.63M	-
Toxicity and Molecular Diagnostic Tests Growth	1491.94%	-	-
Total	3.18B	760.78M	347.85M
Total Growth	318.57%	118.71%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
South Korea	833.37M	565.65M	347.85M
South Korea Growth	47.33%	62.62%	-
USA	2.32B	157.74M	-
USA Growth	1369.68%	-	-
Asia	32.69M	37.39M	-
Asia Growth	-12.55%	-	-
Total	3.18B	760.78M	347.85M
Total Growth	318.57%	118.71%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 30, 2026

Data Sources Report a data error